Bi H, Chen N, Ling G, Yuan S, Huang G, Liu R Nondiabetic renal disease in type 2 diabetic patients: a review of our experience in 220 cases. Ren Fail. 2011;33(1):26-30. doi: 10.3109/0886022X.2010.536292.
Fioretto P, Mauer M Histopathology of diabetic nephropathy. Semin Nephrol. 2007 Mar;27(2):195-207. Review.
KDOQI KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007 Feb;49(2 Suppl 2):S12-154.
Kramer HJ, Nguyen QD, Curhan G, Hsu CY Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003 Jun 25;289(24):3273-7.
Lytvyn Y, Bjornstad P, Pun N, Cherney DZ New and old agents in the management of diabetic nephropathy. Curr Opin Nephrol Hypertens. 2016 May;25(3):232-9. doi: 10.1097/MNH.0000000000000214. Review.
Yuan CM, Nee R, Ceckowski KA, Knight KR, Abbott KC Diabetic nephropathy as the cause of end-stage kidney disease reported on the medical evidence form CMS2728 at a single center. Clin Kidney J. 2017 Apr;10(2):257-262. doi: 10.1093/ckj/sfw112. Epub 2016 Dec 22.
Non Diabetic Causes of Chronic Kidney Disease in Type 2 Diabetic Patients
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
